Evidence map›Paper›PMID 27724856›Full record

ArticleBMC cancer2016

Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma.

Marjorie Flahaut, Nicolas Jauquier, Nadja Chevalier, Katya Nardou, Katia Balmas Bourloud, Jean-Marc Joseph, David Barras, Christian Widmann, Nicole Gross, Raffaele Renella and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Targeting the Retinoic Acid Pathway to Eradicate Cancer Stem Cells.International journal of molecular sciences · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Particulate matter (PMEnvironmental pollution (Barking, Essex : 1987) · 2020
    Article
  19. Targeting cancer stem cells in cholangiocarcinoma (Review).International journal of oncology · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Marjorie FlahautPediatric Hematology-Oncology Research Laboratory, Pediatric Division, University Hospital CHUV, Lausanne, Switzerland.
Nicolas JauquierPediatric Surgery, Pediatric Division, University Hospital CHUV, Lausanne, Switzerland.
Nadja ChevalierPediatric Hematology-Oncology Research Laboratory, Pediatric Division, University Hospital CHUV, Lausanne, Switzerland.
Katya NardouPediatric Hematology-Oncology Research Laboratory, Pediatric Division, University Hospital CHUV, Lausanne, Switzerland.
Katia Balmas BourloudPediatric Hematology-Oncology Research Laboratory, Pediatric Division, University Hospital CHUV, Lausanne, Switzerland.
Jean-Marc JosephPediatric Surgery, Pediatric Division, University Hospital CHUV, Lausanne, Switzerland.
David BarrasSIB Swiss Institute of Bioinformatics, Bioinformatics Core Facility, Lausanne, Switzerland.
Christian WidmannDepartment of Physiology, University of Lausanne, Lausanne, Switzerland.
Nicole GrossPediatric Hematology-Oncology Research Laboratory, Pediatric Division, University Hospital CHUV, Lausanne, Switzerland.
Raffaele RenellaPediatric Hematology-Oncology Research Laboratory, Pediatric Division, University Hospital CHUV, Lausanne, Switzerland.
Annick Mühlethaler-MottetPediatric Hematology-Oncology Research Laboratory, Pediatric Division, University Hospital CHUV, Lausanne, Switzerland. Annick.Muhlethaler@chuv.ch.ORCID 0000-0001-8274-0907
University Hospital of Lausanne · CHSIB Swiss Institute of Bioinformatics · CHUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe successful targeting of neuroblastoma (NB) by associating tumor-initiating cells (TICs) is a major challenge in the development of new therapeutic strategies. The subfamily of aldehyde dehydrogenases 1 (ALDH1) isoenzymes, which comprises ALDH1A1, ALDH1A2, and ALDH1A3, is involved in the synthesis of retinoic acid, and has been identified as functional stem cell markers in diverse cancers. By combining serial neurosphere passages with gene expression profiling, we have previously identified ALDH1A2 and ALDH1A3 as potential NB TICs markers in patient-derived xenograft tumors. In this study, we explored the involvement of ALDH1 isoenzymes and the related ALDH activity in NB aggressive properties.

methodsALDH activity and ALDH1A1/A2/A3 expression levels were measured using the ALDEFLUOR™ kit, and by real-time PCR, respectively. ALDH activity was inhibited using the specific ALDH inhibitor diethylaminobenzaldehyde (DEAB), and ALDH1A3 gene knock-out was generated through the CRISPR/Cas9 technology.

resultsWe first confirmed the enrichment of ALDH1A2 and ALDH1A3 mRNA expression in NB cell lines and patient-derived xenograft tumors during neurosphere passages. We found that high ALDH1A1 expression was associated with less aggressive NB tumors and cell lines, and correlated with favorable prognostic factors. In contrast, we observed that ALDH1A3 was more widely expressed in NB cell lines and was associated with poor survival and high-risk prognostic factors. We also identified an important ALDH activity in various NB cell lines and patient-derived xenograft tumors. Specific inhibition of ALDH activity with diethylaminobenzaldehyde (DEAB) resulted in a strong reduction of NB cell clonogenicity, and TIC self-renewal potential, and partially enhanced NB cells sensitivity to 4-hydroxycyclophosphamide. Finally, the specific knock-out of ALDH1A3 via CRISPR/Cas9 gene editing reduced NB cell clonogenicity, and mediated a cell type-dependent inhibition of TIC self-renewal properties.

conclusionsTogether our data uncover the participation of ALDH enzymatic activity in the aggressive properties and 4-hydroxycyclophosphamide resistance of NB, and show that the specific ALDH1A3 isoenzyme increases the aggressive capacities of a subset of NB cells.

Indexed as

PhenotypeAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyAldehyde OxidoreductasesAnimalsCell Line, TumorDisease Models, AnimalDisease ProgressionEnzyme ActivationGene ExpressionGene Knockout TechniquesHeterograftsHumansIsoenzymesMiceNeuroblastomaAldehyde DehydrogenaseAldehyde Dehydrogenase 1 Familyaldehyde dehydrogenase (NAD(P)+)Aldehyde OxidoreductasesALDH1A2 protein, humanIsoenzymesRetinal Dehydrogenase

Identifiers

PMID27724856
PMCPMC5057398
OpenAlexW2531053278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.